WELCOME TO SKYRIZI COMPLETE.
RESOURCES DESIGNED AROUND YOU.

You may have questions about SKYRIZI. That's why Skyrizi Complete is here to help:

- Make sense of your insurance coverage
- Identify ways you may be able to save on SKYRIZI
- Provide support to help you prepare for your appointments
- Provide supplemental self-injection training, if needed

Your Skyrizi Complete Nurse Ambassador* is committed to helping you understand your treatment, answering your questions, and supporting you to achieve your personal goals while on SKYRIZI. Your Ambassador will be there every step of the way, for as long as you need.

You've signed up for Skyrizi Complete. Here's what to do next:

1. **Before you leave the office, ask your health care professional** which Specialty Pharmacy your prescription is being sent to and write down its number below. This pharmacy will help you plan your SKYRIZI delivery and may follow up with you.

SPECIALTY PHARMACY: _____ **PHONE:** _____

2. **Expect a call from your Ambassador within 1 business day** (the call may come from any area code). They'll help you navigate the prescription process and help you start and stay on track with your prescribed treatment plan.

For questions, or if you have not yet connected with your Nurse Ambassador, please call **1.866.SKYRIZI (1.866.759.7494).**

Skyrizi® COMPLETE

*Nurse Ambassadors are provided by AbbVie and do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

Please see Uses and Important Safety Information on page 2.

Please see full Prescribing Information, including Medication Guide, or visit https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

Skyrizi®
risankizumab-rzaa

Uses and Important Safety Information About SKYRIZI® (risankizumab-rzaa)[1]

SKYRIZI Uses[1]

SKYRIZI® (risankizumab-rzaa) is a prescription medicine used to treat adults:

- with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
- with active psoriatic arthritis (PsA).

Important Safety Information[1]

What is the most important information I should know about SKYRIZI® (risankizumab-rzaa)?

SKYRIZI is a prescription medicine that may cause serious side effects, including:

Serious allergic reactions:

- Stop using SKYRIZI and get emergency medical help right away if you get any of the following symptoms of a serious allergic reaction:
  - fainting, dizziness, feeling lightheaded (low blood pressure)
  - swelling of your face, eyelids, lips, mouth, tongue, or throat
  - trouble breathing or throat tightness
  - chest tightness
  - skin rash, hives
  - itching

Infections:

SKYRIZI may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis (TB) before starting treatment with SKYRIZI and may treat you for TB before you begin treatment with SKYRIZI if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with SKYRIZI.

- Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
  - fever, sweats, or chills
  - cough
  - shortness of breath
  - blood in your mucus (phlegm)
  - muscle aches
  - warm, red, or painful skin or sores on your body different from your psoriasis
  - weight loss
  - diarrhea or stomach pain
  - burning when you urinate or urinating more often than normal

Do not use SKYRIZI if you are allergic to risankizumab-rzaa or any of the ingredients in SKYRIZI. See the Medication Guide or Consumer Brief Summary for a complete list of ingredients.

Before using SKYRIZI, tell your healthcare provider about all of your medical conditions, including if you:

- have any of the conditions or symptoms listed in the section **"What is the most important information I should know about SKYRIZI?"**
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Medications that interact with the immune system may increase your risk of getting an infection after receiving live vaccines. You should avoid receiving live vaccines right before, during, or right after treatment with SKYRIZI. Tell your healthcare provider that you are taking SKYRIZI before receiving a vaccine.
- are pregnant or plan to become pregnant. It is not known if SKYRIZI can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if SKYRIZI passes into your breast milk.
- become pregnant while taking SKYRIZI. You are encouraged to enroll in the Pregnancy Registry, which is used to collect information about the health of you and your baby. Talk to your healthcare provider or call 1-877-302-2161 to enroll in this registry.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of SKYRIZI?

SKYRIZI may cause serious side effects. See "What is the most important information I should know about SKYRIZI?"

The most common side effects of SKYRIZI in people treated for plaque psoriasis and psoriatic arthritis include: upper respiratory infections, headache, feeling tired, injection site reactions, and fungal skin infections.

These are not all the possible side effects of SKYRIZI. Call your doctor for medical advice about side effects.

Use SKYRIZI exactly as your healthcare provider tells you to use it.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help.
Visit AbbVie.com/myAbbVieAssist to learn more.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full Prescribing Information, including Medication Guide, or visit https://www.rxabbvie.com/pdf/skyrizi_pi.pdf.

abbvie

US-SKZ-230195

Skyrizi® risankizumab-rzaa

Skyrizi® COMPLETE

FAXING INSTRUCTIONS:
Fax to Skyrizi Complete **(1.678.727.0690)**

Enrollment and Prescription Form

SPSA-080123-A08

The health care professional (HCP) and the patient or legally authorized person should fill out this form completely before leaving the office.
Sections in **BLUE** (1, 2, 3, 4) are necessary for enrollment into Skyrizi Complete. Required fields are marked with an asterisk (*).

1 PATIENT DEMOGRAPHIC SHEET*

To be faxed by HCP with the Enrollment and Prescription Form.

When faxing this form, please include the patient demographic sheet, ensuring the following patient information is included: full home address, email address, medical and prescription insurance information, and any relevant clinical details (such as prior therapies). **Additionally, ensure the patient's entire Social Security number is redacted from the demographic sheet (if applicable). Failure to include the demographic sheet may result in delayed enrollment.**

2 PATIENT'S INFORMATION

-To be completed by patient or legally authorized person. Please print clearly.

First Name:* Last Name:* Date of Birth: / / Gender: ☐ M ☐ F

Mobile Phone: Email Address:* ☐ Spanish interpreter needed

When did you start on treatment?* ☐ Not Yet Started ☐ 0-3 Months Ago ☐ 4-6 Months Ago ☐ 7-12 Months Ago ☐ Over 12 Months Ago

▶ ☐ I consent to receive automated and recurring text messages from Complete Treatment Support program, including service updates, medication reminders and marketing messages to the provided mobile number. Message and data rates may apply. I am not required to consent as a condition of receiving goods or services. I can text HELP to 29279 for help, or call 1-866-759-7494. I can text STOP to 29279 to unsubscribe at any time. **View full Terms and Conditions**.

By enrolling, you may receive your own Nurse Ambassador provided by AbbVie. Ambassadors do not work under the direction of your health care professional (HCP) or give medical advice. They are trained to direct patients to their HCP for treatment-related advice, including further referrals.

▶ ☐ I consent to the collection, use, and disclosure of my health-related personal data to receive communications from AbbVie regarding its products, programs, services, clinical trials, research opportunities and for online targeted advertising, as further described in the **"How we may use Personal Data," "How we may disclose Personal Data,"** and **"Cookies and similar tracking and data collection technologies"** sections of our **Privacy Notice**. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting **"Your Privacy Choices"** on AbbVie's website.

For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit **https://abbv.ie/PrivacyPatient**

Through my submission of the enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie's Privacy Notice in the **"How we may disclose Personal Data"** section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting **"Your Privacy Choices"** on AbbVie's website.

▼ FOR HEALTH CARE PROVIDER USE ONLY ▼

3 DIAGNOSIS*

☐ Plaque Psoriasis (Ps) ☐ Psoriatic Arthritis (PsA)

4 PRESCRIBER INFORMATION

Prescriber's Last Name*: Street Address*: State*: ZIP*:

Prescriber's Phone*: Office Fax #*: NPI #*:

I would like to receive a copy: ☐ **Benefits Verification Summary** ☐ Prior Authorization Form

5 INJECTION TRAINING

☐ I request supplemental injection training and/or administration, if needed, for this patient. Order valid for up to one year.
Fill out and sign pharmacy prescription below.

6 PHARMACY PRESCRIPTION - OPTIONAL - Fill out and sign corresponding prescription below.

Patient's preferred Specialty Pharmacy: _____ ☐ Check if faxed to Specialty Pharmacy

☐ Plaque Psoriasis (Ps) ☐ Psoriatic Arthritis (PsA)

Choose one SKYRIZI presentation:
☐ SKYRIZI PEN 150 mg
☐ SKYRIZI SYRINGE 150 mg

Check appropriate boxes to indicate quantity to dispense (one dose each) and directions:
☐ Initiation at Week 0: Inject 150 mg SC
☐ Initiation at Week 4: Inject 150 mg SC
☐ Inject 150 mg SC every 12 weeks thereafter
Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed SKYRIZI to the previously identified patient and that I provided the patient with a description of the Skyrizi Complete patient support program. I authorize Skyrizi Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan (if applicable).

Prescriber's Signature: (REQUIRED) X _____ **Date:** ___/___/___

7 SKYRIZI SHIPPING PREFERENCES

Date needed: ___/___/___ **First Dose Address:** ☐ Prescriber ☐ Patient **Follow-Up Doses Address:** ☐ Prescriber ☐ Patient

8 SKYRIZI COMPLETE PRESCRIPTION - Required in the event a patient experiences an insurance delay or denial.

Eligible patients must have (1) commercial insurance, (2) a valid Rx for SKYRIZI, and (3) experienced a delay or denial in insurance determination. See program Terms and Conditions on the following page. Please complete the full form as well as this section and sign below. **Prescription to be filled through an AbbVie-authorized pharmacy.** I understand that faxing this form to SKYRIZI Complete will result in an original copy being simultaneously transmitted to the AbbVie-authorized pharmacy under this section.

Choose one SKYRIZI presentation:
☐ SKYRIZI PEN 150 mg
☐ SKYRIZI SYRINGE 150 mg

Inject 150 mg SC at Week 0, Week 4, and every 12 weeks thereafter
Quantity: 1 dose of 150 mg
Refills: _____

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed SKYRIZI to the previously identified patient and that I provided the patient with a description of the Skyrizi Complete patient support program. I authorize Skyrizi Complete to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy. I understand that the no charge resource through Skyrizi Complete may support patients who are experiencing an insurance access challenge for SKYRIZI until coverage is obtained, and I confirm that I will support the above-identified patient in seeking to secure such coverage as I deem appropriate. I certify that I will not seek reimbursement from any third party payor for any no charge product dispensed by an AbbVie authorized pharmacy.

Prescriber's Signature: (REQUIRED) X _____ **Date:** ___/___/___

For information on how we collect and process your personal data, including the categories we collect, purposes for their collection, and disclosures to third parties, visit **https://abbv.ie/PrivacyHCP**

Please see Important Safety Information and full Indications on page 4. Please see full Prescribing Information.

Skyrizi® risankizumab-rzaa

Indications and Important Safety Information[1]

SKYRIZI Indications[1]

Plaque Psoriasis: SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Psoriatic Arthritis: SKYRIZI is indicated for the treatment of active psoriatic arthritis in adults.

Important Safety Information[1]

Hypersensitivity Reactions

SKYRIZI® (risankizumab-rzaa) is contraindicated in patients with a history of serious hypersensitivity reaction to risankizumab-rzaa or any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of SKYRIZI. If a serious hypersensitivity reaction occurs, discontinue SKYRIZI and initiate appropriate therapy immediately.

Infection

SKYRIZI may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

In psoriatic arthritis phase 3 trials, the incidence of hepatic events was higher with SKYRIZI compared to placebo.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

SKYRIZI COMPLETE PRESCRIPTION TERMS & CONDITIONS

Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for SKYRIZI for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for SKYRIZI at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.

Reference: 1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.

Please see full Prescribing Information.

abbvie

US-SKZ-230195 July 2023

Skyrizi® risankizumab-rzaa